Natural products as probes of cell biology:: 20 years of didemnin research

被引:122
作者
Vera, MD [1 ]
Joullié, MM [1 ]
机构
[1] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA
关键词
apoptosis; biological activity; clinical studies; didemnins; mechanism of action;
D O I
10.1002/med.10003
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The discovery of the didemnin family of marine depsipeptides launched an exciting and intriguing chapter in natural product chemistry. The unusual structure of the didemnin congeners has led to several total syntheses by research groups from around the world. The impressive in vitro and in vivo biological activities of the didemnins resulted in the first human clinical trials in the U.S. of a marine natural product against cancer, and additional clinical trials of a second-generation didemnin, dehydrodidemnin B (aplidine). are underway. As we mark the 20-year anniversary of the discovery of the didemnins, this class of natural products continues to stimulate active research in fields ranging from synthetic and medicinal chemistry to clinical oncology and cell biology. While some progress was made in dissecting the molecular mechanism of action and in establishing structure-activity relationships, there are still more questions than answers. This review covers the recent didemnin literature, highlighting the work directed towards understanding how this group of natural products interact with fundamental processes such as cell proliferation, protein biosynthesis, and apoptosis, The didemnin field illustrates how natural product chemistry may be used as a critical toot for the study of cell biology. (C) 2002 John Wiley Sons, Inc.
引用
收藏
页码:102 / 145
页数:44
相关论文
共 147 条
[31]   INVIVO EFFECT OF DIDEMNIN-B ON 2 TUMORS OF THE RAT [J].
FIMIANI, V .
ONCOLOGY, 1987, 44 (01) :42-46
[32]  
FLEMING SA, 1995, TETRAHEDRON, V51, P12479
[33]  
GERWICK W H, 1987, Journal of Pharmacy Technology, V3, P136
[34]  
GLOER JB, 1983, STRUCTURES DIDEMNINS
[35]   Didemnin B in favourable histology non-Hodgkin's lymphoma - A phase II study of the National Cancer Institute of Canada Clinical Trials Group [J].
Goss, G ;
Muldal, A ;
Lohmann, R ;
Taylor, M ;
Lopez, P ;
Armitage, G ;
Steward, WP .
INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) :257-260
[36]   FURTHER EVIDENCE THAT ELONGATION FACTOR-1 REMAINS BOUND TO RIBOSOMES DURING PEPTIDE CHAIN ELONGATION [J].
GRASMUK, H ;
NOLAN, RD ;
DREWS, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1977, 79 (01) :93-102
[37]   NEW CONCEPT OF FUNCTION OF ELONGATION FACTOR-1 IN PEPTIDE CHAIN ELONGATION [J].
GRASMUK, H ;
NOLAN, RD ;
DREWS, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1976, 71 (01) :271-279
[38]   DIDEMNIN-B INDUCES CELL-DEATH BY APOPTOSIS - THE FASTEST INDUCTION OF APOPTOSIS EVER DESCRIBED [J].
GRUBB, DR ;
WOLVETANG, EJ ;
LAWEN, A .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 215 (03) :1130-1136
[39]   Mitochondrial cytochrome c release is caspase-dependent and does not involve mitochondrial permeability transition in didemnin B-induced apoptosis [J].
Grubb, DR ;
Ly, JD ;
Vaillant, F ;
Johnson, KL ;
Lawen, A .
ONCOGENE, 2001, 20 (30) :4085-4094
[40]  
GSCHWENDT M, 1989, IMMUNOBIOLOGY, V179, P1